Program
Varenicline
Also written as “varenicline”, “Varenicline Tartrate” and “varenicline (CP-526,555)”.
Its studies are mostly in Smoking Cessation · Dry Eye Syndromes · Smoking · Trigeminal Neuralgia · Cigarette Smoking, led by 6 companies.
Drug pageVarenicline: every studyMany companies study it; this page follows only the 44 they lead. All 254 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 320 open or running | phase 4since Jan 3, 2008 | Aug 29, 2005 | none ahead |
| Viatris | 60 open or running | phase 3since Jul 25, 2019 | Aug 15, 2018 | none ahead |
| Corxel Pharmaceuticalsits history only | 20 open or running | phase 3since May 13, 2022 | May 13, 2022 | none ahead |
| Rose Research Centerits history only | 20 open or running | phase 4since Jun 6, 2019 | Jun 6, 2019 | none ahead |
| Kriya Therapeuticsits history only | 11 open or running | phase 2since Apr 17, 2026 | Apr 17, 2026 | Feb 2029phase 2 · NCT07596485 |
| SRI Internationalits history only | 10 open or running | no phasesince Mar 8, 2006 | Mar 8, 2006 | none ahead |
Also a collaborator on its studies: GlaxoSmithKline.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Viatris only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 15, 2018First study: phase 2 study in Dry Eye SyndromesFirst studyNCT03636061 · 182 enrolled · United States
- Sep 26, 2018Phase 2 study in Dry Eye SyndromesNCT03688802 · 18 enrolled · United States
- Mar 11, 2019Phase 2 study in Dry Eye SyndromesNCT03873246 · 123 enrolled · Mexico
- Jul 25, 2019Phase 3 study in Dry Eye SyndromesNCT04036292 · 758 enrolled · United States
- Aug 27, 2019Phase 1 study in Healthy SubjectsNCT04072146 · 22 enrolled · United States
- Jun 28, 2021Phase 2 study in Neurotrophic KeratopathyNCT04957758 · 113 enrolled · United States
TargetBeta
“Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cytisinerule | Achieve Life Sciences | phase 3 | 13 |
Studies
All 6 Viatris leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04957758Neurotrophic Keratopathy · United States | 2 | Completed | Jan 27, 2023 | 113 |
| NCT04072146Healthy Subjects · United States | 1 | Completed | Nov 15, 2019 | 22 |
| NCT04036292Dry Eye Syndromes · United States | 3 | Completed | Apr 10, 2020 | 758 |
| NCT03873246Dry Eye Syndromes · Mexico | 2 | Completed | Jan 7, 2020 | 123 |
| NCT03688802Dry Eye Syndromes · United States | 2 | Completed | Sep 30, 2019 | 18 |
| NCT03636061Dry Eye Syndromes · United States | 2 | Completed | Sep 26, 2018 | 182 |
How it is read
Names in the registry
- “varenicline”, 11 entries
- “Varenicline Tartrate”, 7 entries
- “Varenicline”, 6 entries
- “varenicline (CP-526,555)”, 6 entries
- “CP-526,555 (varenicline)”, 4 entries
Conditions, from the studies’ own filings
- Smoking Cessation, 28 studies
- Dry Eye Syndromes, 6 studies
- Smoking, 2 studies
- Trigeminal Neuralgia, 1 study
- Cigarette Smoking, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.